Clinical Trial Update: NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating NEROFE in combination with doxorubicin for KRAS-mutant ST2-positive solid tumors is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kras-mutant Solid Tumors
• Solid Tumors

Drugs mentioned

• Doxorubicin (doxorubicin)
• NEROFE

Snippet

Sponsor: Georgetown University | Conditions: Solid Tumor, KRAS Mutation-Related Tumors | Phase 1 | Status: RECRUITING